|
Disease
|
No.
|
ELiA™ TRAb (median IU/L)
|
Range (minimum–maximum)
|
Significant difference from NC (p)
|
|---|
|
u-GD
|
57
|
10.0
|
0.7− > 50
|
< 0.0001
|
|
t-GD
|
34
|
5.95
|
1.6− > 50
|
< 0.0001
|
|
GD/GO
|
15
|
16.3
|
2.2− > 50
|
< 0.0001
|
|
NTMG
|
52
|
1.4
|
0.6–2.3
|
ns
|
|
TA/TMG
|
20
|
1.3
|
1.0–3.3
|
ns
|
|
HT
|
86
|
1.1
|
0.1–2.7
|
ns
|
|
NTAD
|
55
|
2.2
|
1.0–4.4
|
ns
|
|
NC
|
120
|
1.4
|
0.7–3.8
|
ns
|
|
Overall
|
439
| | | |
- u-GD Graves’ disease before treatment, t-GD GD on treatment, GD/GO Graves’ patients with orbitopathy, NTMG multinodular non-toxic goiter, TA/TMG toxic adenoma/toxic multinodular goiter, HT Hashimoto’s thyroiditis, NTAD non-thyroid autoimmune diseases, NC normal controls
